

Company name---Alpha TAU Medical----- * Website-----www.alphatau.com- *

CTO name Ronen Segal-----*

Medtech is Accelerating _ Trends and Focus Area

Title of the Presentation: What makes Alpha Tau's novel cancer treatment most promising in the booming market of Radioisotope treatments ?

By Ronen Segal, CTO, Alpha Tau Medical

- **Executive Summary / Investment Rational**

Alpha DaRT technology disrupts the Oncology field with a novel solid tumor treatment based on Alpha particles. With the potential to treat millions of cancer patients around the world, Alpha Tau has managed to take the technology from the bench to a very successful first-in-human trial in the treatment of Skin and Head & Neck cancers. Was granted FDA breakthrough device designation for GBM and Skin Cancers. Recruiting for a pivotal multicenter trial for commercialization. Treated first patients with pancreatic cancer. Partnering with top cancer research centers including Memorial Sloan Kettering, McGill University and many more. Raised more than \$100M in an IPO in the NASDAQ (DRTS). A very strong management team that led medical tech to big successes like Brainsway and Novocure.

- **Core Technology**

What is the technology, its uniqueness, and its value proposition?

Alpha DaRT™ Technology is based on Alpha particles that are known to be very destructive to tumor cells. They cause direct, irreparable damage to the cell DNA and lead to cell death. Using small, extremely precise amounts of radioactive radium-224 affixed to metal sources that are inserted into the tumor itself. When radium-224 decays, it releases radioactive atoms with short lifespans that diffuse inside the tumor. These atoms emit short-range alpha radiation that damages and kills cancer cells within a short period of time. This technology has the potential for treating millions of patients with no good standard treatment with minimal side effects.

- **Product Profile/Pipeline**

The first indication in humans was recurrent Skin and Head & Neck patients with more than 80% complete response. Next, we have clinical studies in Breast, Pancreas, Prostate, Liver mets., and GYN cancers.

- **Business Strategy**

Execute clinical validation for each product/indication treatment, get reimbursement, and sell treatment kits. No capital investment is needed. Direct sales in the US. Current distribution agreement in other geographies.

- **What's Next?**

Open many more study sites in different indications and territories. Build additional radioactive production facilities globally.

